Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori
Gut and Liver
; : 452-456, 2012.
Article
em En
| WPRIM
| ID: wpr-58003
Biblioteca responsável:
WPRO
ABSTRACT
BACKGROUND/AIMS:
This study assessed the efficacy of a rifaximin plus levofloxacin-based rescue regimen in patients that had failed both triple and quadruple standard regimens for the eradication of Helicobacter pylori.METHODS:
We treated patients for H. pylori between August 2009 and April 2011. The triple regimen consisted of combined treatment with amoxicillin, clarithromycin, and pantoprazole for 1 week. For failed cases, a quadruple regimen of tetracycline, metronidazole, bismuth dicitrate, and lansoprazole for 1 week was administered. The rescue regimen for persistently refractory cases was rifaximin 200 mg t.i.d., levofloxacin 500 mg q.d., and lansoprazole 15 mg b.i.d. for 1 week.RESULTS:
In total, 482 patients were enrolled in this study. The eradication rates associated with the first and second regimens were 58% and 60%, respectively. Forty-seven out of 58 patients who failed with the second-line regimen received rifaximin plus levofloxacin-based third-line therapy. The eradication rate for the third regimen was 65%. The cumulative eradication rates were 58%, 85%, and 96% for each regimen, respectively.CONCLUSIONS:
A rifaximin plus levofloxacin-based regimen could be an alternative rescue therapy in patients with resistance to both triple and quadruple regimens for the eradication of H. pylori.Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Rifamicinas
/
Tetraciclina
/
Bismuto
/
Ofloxacino
/
Helicobacter pylori
/
Helicobacter
/
Claritromicina
/
2-Piridinilmetilsulfinilbenzimidazóis
/
Amoxicilina
/
Metronidazol
Limite:
Humans
Idioma:
En
Revista:
Gut and Liver
Ano de publicação:
2012
Tipo de documento:
Article